|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Akhtar N and Bansal JG: Risk factors of
lung cancer in nonsmoker. Curr Probl Cancer. 41:328–339. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ihde DC: Chemotherapy of lung cancer. N
Engl J Med. 327:1434–1441. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hoffman PC, Mauer AM and Vokes EE: Lung
cancer. Lancet. 355:479–485. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gou LY, Niu FY, Wu YL and Zhong WZ:
Differences in driver genes between smoking-related and
non-smoking-related lung cancer in the Chinese population. Cancer.
121:3069–3079. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
King A, Selak MA and Gottlieb E: Succinate
dehydrogenase and fumarate hydratase: Linking mitochondrial
dysfunction and cancer. Oncogene. 25:4675–4682. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ming Z, Jiang M, Li W, Fan N, Deng W,
Zhong Y, Zhang Y, Zhang Q and Yang S: Bioinformatics analysis and
expression study of fumarate hydratase in lung cancer. Thoracic
Cancer. 5:543–549. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen T, Wang T, Liang W, Zhao Q, Yu Q, Ma
CM, Zhuo L, Guo D, Zheng K, Zhou C, et al: PAK4 phosphorylates
fumarase and blocks TGFβ-induced cell growth arrest in lung cancer
cells. Cancer Res. 79:1383–1397. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang H, Dong S, Liu Y, Ma F, Fang J, Zhang
W, Shao S, Shen H and Jin J: DAB2 suppresses gastric cancer
migration by regulating the Wnt/β-catenin and Hippo-YAP signaling
pathways. Transl Cancer Res. 9:1174–1184. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tian X and Zhang Z: miR-191/DAB2 axis
regulates the tumorigenicity of estrogen receptor-positive breast
cancer. IUBMB Life. 70:71–80. 2018. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hocevar BA: Loss of disabled-2 expression
in pancreatic cancer progression. Sci Rep. 9:75322019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu HT, Yang LH, Li QC, Liu SL, Liu D, Xie
XM and Wang EH: Disabled-2 and Axin are concurrently colocalized
and underexpressed in lung cancers. Hum Pathol. 42:1491–1498. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xie XM, Zhang ZY, Yang LH, Yang DL, Tang
N, Zhao HY, Xu HT, Li QC and Wang EH: Aberrant hypermethylation and
reduced expression of disabled-2 promote the development of lung
cancers. Int J Oncol. 43:1636–1642. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li C, Chen J, Chen T, Xu Z, Xu C, Ding C,
Wang Y, Lei Z, Zhang HT and Zhao J: Aberrant hypermethylation at
sites-86 to 226 of DAB2 gene in non-small cell lung cancer. Am J
Med Sci. 349:425–431. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Du L, Zhao Z, Ma X, Hsiao TH, Chen Y,
Young E, Suraokar M, Wistuba I, Minna JD and Pertsemlidis A:
miR-93-directed downregulation of DAB2 defines a novel oncogenic
pathway in lung cancer. Oncogene. 33:4307–4315. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang L, Huang P, Li Q, Wang D and Xu CX:
miR-134-5p promotes stage I lung adenocarcinoma metastasis and
chemoresistance by targeting DAB2. Mol Ther Nucleic Acids.
18:627–637. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hardie DG: AMPK-sensing energy while
talking to other signaling pathways. Cell Metab. 20:939–952. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kahn BB, Alquier T, Carling D and Hardie
DG: AMP-activated protein kinase: Ancient energy gauge provides
clues to modern understanding of metabolism. Cell Metab. 1:15–25.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ashrafizadeh M, Mirzaei S, Hushmandi K,
Rahmanian V, Zabolian A, Raei M, Farahani MV, Goharrizi MASB, Khan
H, Zarrabi A and Samarghandian S: Therapeutic potential of AMPK
signaling targeting in lung cancer: Advances, challenges and future
prospects. Life Sci. 278:1196492021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tong WH, Sourbier C, Kovtunovych G, Jeong
SY, Vira M, Ghosh M, Romero VV, Sougrat R, Vaulont S, Viollet B, et
al: The glycolytic shift in fumarate-hydratase-deficient kidney
cancer lowers AMPK levels, increases anabolic propensities and
lowers cellular iron levels. Cancer Cell. 20:315–327. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yuan SSF, Hou MF, Hsieh YC, Huang CY, Lee
YC, Chen YJ and Lo S: Role of MRE11 in cell proliferation, tumor
invasion, and DNA repair in breast cancer. J Natl Cancer Inst.
104:1485–1502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang YY, Chen YK, Lo S, Chi TC, Chen YH,
Hu SC, Chen YW, Jiang SS, Tsai FY, Liu W, et al: MRE11 promotes
oral cancer progression through RUNX2/CXCR4/AKT/FOXA2 signaling in
a nuclease-independent manner. Oncogene. 40:3510–3532. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC,
Chen YC, Tsai CH, Chiu WC, Chu-Sung Hu S, Lu CW, et al: Resistin
facilitates breast cancer progression via TLR4-mediated induction
of mesenchymal phenotypes and stemness properties. Oncogene.
37:589–600. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Huang JY, Wang YY, Lo S, Tseng LM, Chen
DR, Wu YC, Hou MF and Yuan SF: Visfatin mediates malignant
behaviors through adipose-derived stem cells intermediary in breast
cancer. Cancers (Basel). 12:292019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang YY, Chen HD, Lo S, Chen YK, Huang YC,
Hu SC, Hsieh YC, Hung AC, Hou MF and Yuan SF: Visfatin enhances
breast cancer progression through CXCL1 induction in
tumor-associated macrophages. Cancers (Basel). 12:35262020.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Udupa S, Nguyen S, Hoang G, Nguyen T,
Quinones A, Pham K, Asaka R, Nguyen K, Zhang C, Elgogary A, et al:
Upregulation of the glutaminase II pathway contributes to glutamate
production upon glutaminase 1 inhibition in pancreatic cancer.
Proteomics. 19:18004512019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bardella C, Olivero M, Lorenzato A, Geuna
M, Adam J, O'Flaherty L, Rustin P, Tomlinson I, Pollard PJ and Di
Renzo MF: Cells lacking the fumarase tumor suppressor are protected
from apoptosis through a hypoxia-inducible factor-independent,
AMPK-dependent mechanism. Mol Cell Biol. 32:3081–3094. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Barker KT, Bevan S, Wang R, Lu YJ,
Flanagan AM, Bridge JA, Fisher C, Finlayson CJ, Shipley J and
Houlston RS: Low frequency of somatic mutations in the FH/multiple
cutaneous leiomyomatosis gene in sporadic leiomyosarcomas and
uterine leiomyomas. Br J Cancer. 87:446–448. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kiuru M, Lehtonen R, Arola J, Salovaara R,
Järvinen H, Aittomäki K, Sjöberg J, Visakorpi T, Knuutila S, Isola
J, et al: Few FH mutations in sporadic counterparts of tumor types
observed in hereditary leiomyomatosis and renal cell cancer
families. Cancer Res. 62:4554–4557. 2002.PubMed/NCBI
|
|
30
|
Sciacovelli M, Gonçalves E, Johnson TI,
Zecchini VR, da Costa AS, Gaude E, Drubbel AV, Theobald SJ, Abbo
SR, Tran MG, et al: Fumarate is an epigenetic modifier that elicits
epithelial-to-mesenchymal transition. Nature. 537:544–547. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Schmidt C, Sciacovelli M and Frezza C:
Fumarate hydratase in cancer: A multifaceted tumour suppressor.
Semin Cell Dev Biol. 98:15–25. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ge X, Li M, Yin J, Shi Z, Fu Y, Zhao N,
Chen H, Meng L, Li X, Hu Z, et al: Fumarate inhibits PTEN to
promote tumorigenesis and therapeutic resistance of type2 papillary
renal cell carcinoma. Mol Cell. 82:1249–1260.e7. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Johnson TI, Costa AS, Ferguson AN and
Frezza C: Fumarate hydratase loss promotes mitotic entry in the
presence of DNA damage after ionising radiation. Cell Death Dis.
9:9132018. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Isaacs JS, Jung YJ, Mole DR, Lee S,
Torres-Cabala C, Chung YL, Merino M, Trepel J, Zbar B, Toro J, et
al: HIF overexpression correlates with biallelic loss of fumarate
hydratase in renal cancer: Novel role of fumarate in regulation of
HIF stability. Cancer Cell. 8:143–153. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sullivan LB, Martinez-Garcia E, Nguyen H,
Mullen AR, Dufour E, Sudarshan S, Licht JD, Deberardinis RJ and
Chandel NS: The proto-oncometabolite fumarate binds glutathione to
amplify ROS-dependent signaling. Mol Cell. 51:236–248. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gonçalves E, Sciacovelli M, Costa ASH,
Tran MGB, Johnson TI, Machado D, Frezza C and Saez-Rodriguez J:
Post-translational regulation of metabolism in fumarate hydratase
deficient cancer cells. Metab Eng. 45:149–157. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chang YJ, Huang JY, Lin CH and Wang BY:
Survival and treatment of lung cancer in Taiwan between 2010 and
2016. J Clin Med. 10:46752021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang BY, Huang JY, Cheng CY, Lin CH, Ko J
and Liaw YP: Lung cancer and prognosis in Taiwan: A
population-based cancer registry. J Thorac Oncol. 8:1128–1135.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sciacovelli M and Frezza C: Fumarate
drives EMT in renal cancer. Cell Death Differ. 24:1–2. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Hou C, Ishi Y, Motegi H, Okamoto M, Ou Y,
Chen J and Yamaguchi S: Overexpression of CD44 is associated with a
poor prognosis in grade II/III gliomas. J Neurooncol. 145:201–210.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhang JG, Xu C, Zhang L, Zhu W, Shen H and
Deng HW: Identify gene expression pattern change at transcriptional
and post-transcriptional levels. Transcription. 10:137–146. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Martin J, Herbert B and Hocevar B:
Disabled-2 downregulation promotes epithelial-to-mesenchymal
transition. Br J Cancer. 103:1716–1723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sun C, Yao X, Jiang Q and Sun X: miR-106b
targets DAB2 to promote hepatocellular carcinoma cell proliferation
and metastasis. Oncol Lett. 16:3063–3069. 2018.PubMed/NCBI
|
|
44
|
Yang YF, Wang YY, Hsiao M, Lo S, Chang YC,
Jan YH, Lai TC, Lee YC, Hsieh YC and Yuan SF: IMPAD1 functions as
mitochondrial electron transport inhibitor that prevents ROS
production and promotes lung cancer metastasis through the
AMPK-Notch1-HEY1 pathway. Cancer Lett. 485:27–37. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
He K, Guo X, Liu Y, Li J, Hu Y, Wang D and
Song J: TUFM downregulation induces epithelial-mesenchymal
transition and invasion in lung cancer cells via a mechanism
involving AMPK-GSK3β signaling. Cell Mol Life Sci. 73:2105–2121.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Han SY, Jeong YJ, Choi Y, Hwang SK, Bae YS
and Chang YC: Mitochondrial dysfunction induces the invasive
phenotype, and cell migration and invasion, through the induction
of AKT and AMPK pathways in lung cancer cells. Int J Mol Med.
42:1644–1652. 2018.PubMed/NCBI
|
|
47
|
Wu SB, Wu YT, Wu TP and Wei YH: Role of
AMPK-mediated adaptive responses in human cells with mitochondrial
dysfunction to oxidative stress. Biochim Biophys Acta.
1840:1331–1344. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Godlewski J, Nowicki MO, Bronisz A, Nuovo
G, Palatini J, De Lay M, Van Brocklyn J, Ostrowski MC, Chiocca EA
and Lawler SE: MicroRNA-451 regulates LKB1/AMPK signaling and
allows adaptation to metabolic stress in glioma cells. Mol Cell.
37:620–632. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Gongol B, Sari I, Bryant T, Rosete G and
Marin T: AMPK: An epigenetic landscape modulator. Int J Mol Sci.
19:32382018. View Article : Google Scholar : PubMed/NCBI
|
